Novartis AG ADR (NVS)vsOPTIMIZERx Corp (OPRX)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
OPRX
OPTIMIZERx Corp
$6.23
+1.47%
HEALTHCARE · Cap: $120.08M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 51603% more annual revenue ($56.58B vs $109.43M). NVS leads profitability with a 23.9% profit margin vs 4.7%. OPRX appears more attractively valued with a PEG of 1.61. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OPRX
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for OPRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 27.7%
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 4.2% — below average capital efficiency
4.7% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : OPRX
The strongest argument for OPRX centers on Price/Book, Operating Margin.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : OPRX
The primary concerns for OPRX are PEG Ratio, Market Cap, Return on Equity. Thin 4.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while OPRX is a value play — different risk/reward profiles.
OPRX carries more volatility with a beta of 1.28 — expect wider price swings.
OPRX is growing revenue faster at -0.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 49/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →OPTIMIZERx Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
OptimizeRx Corporation is a digital health company providing communications solutions for life sciences companies, physicians, and patients. The company is headquartered in Rochester, Michigan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?